Ketamine and NAP patent for ADNP syndrome treatment
Summary
Ketamine and NAP patent for ADNP syndrome treatment
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
KETAMINE AND KETAMINE/NAP FOR TREATMENT OF ADNP SYNDROME AND RELATED NEUROLOGICAL CONDITIONS
Application US20260097005A1 Kind: A1 Apr 09, 2026
Inventors
Sandra SERMONE, Matthew Christopher DAVIS
Abstract
The invention is directed to a method of increasing the expression of Activity-Dependent Neuroprotector Protein (ADNP) in at least one mammalian cell showing insufficient ADNP expression levels, comprising administering to the at least one mammalian cell an effective amount of ketamine or a combination of ketamine and ADNP-Derived Neuroprotective Peptide (NAP).
CPC Classifications
A61K 31/135 A61K 38/18
Filing Date
2025-10-08
Application No.
19353020
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.